On the upside
Sarepta Therapeutics (Nasdaq: SRPT) regained compliance for Nasdaq listing by maintaining a $1 minimum closing bid price for ten consecutive business days.
Roper Industries (NYSE: ROP) reported higher second quarter earnings and announced the acquisition of Sunquest Information Systems for approximately $1.4 billion in cash.
On the downside
Credit Suisse analyst Michael Exstein said that J.C. Penney's (NYSE: JCP) efforts to revitalize its brand with the new branded shops within a department store concept will be challenging.
Second quarter earnings for Lufkin (Nasdaq: LUFK) fell short of analyst expectations and the oilfield services provider forecast earnings and revenue that missed analyst estimates.
Needham downgraded Progenics Pharmaceuticals (Nasdaq: PGNX) after the Food and Drug Administration requested additional clinical data for its opioid-induced constipation treatment Relistor.
In the broad market, declining issues outpaced advancers by a margin of 10 to 9 on the NYSE and by nearly 2 to 1 Nasdaq. The Russell 2000 which tracks small cap stocks lost 4 points to 791.